Karyopharm Therapeutics (KPTI) has shared an update.
Michael Mason has announced his resignation as Executive Vice President, Chief Financial Officer, and Treasurer of Karyopharm Therapeutics to explore new professional opportunities. He will continue his duties until November 5, 2024, while the company seeks a successor. Mason has agreed to a Transition Agreement ensuring a $100,000 lump sum and a consulting role until March 1, 2025, post-resignation, provided certain conditions are met. In this role, his equity awards will keep vesting, and he will receive an hourly fee for consulting services beyond five hours monthly.
Learn more about KPTI stock on TipRanks’ Stock Analysis page.
